Degrinta (Degarelix) is a gonadotropin-releasing hormone (GnRH) antagonist used for the management of advanced prostate cancer. Unlike GnRH agonists, Degarelix reduces testosterone levels quickly without causing an initial testosterone surge. This makes it a preferred option for patients where rapid testosterone suppression is critical.

Uses

Advanced Prostate Cancer:

• Used to suppress testosterone levels, which slows the growth of prostate cancer.

Degarelix works by directly binding to and blocking GnRH receptors in the pituitary gland. This suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a rapid decrease in testosterone production by the testes.

Dosages

Initial Dose:

• 240 mg administered as two subcutaneous injections of 120 mg each.

Maintenance Dose:

• 80 mg administered as a single subcutaneous injection every 28 days.

Note: It is essential to follow the dosing schedule for effective testosterone suppression.

Side Effects

Common side effects include:

1. Injection site reactions (pain, redness, swelling)
2. Hot flashes
3. Increased liver enzyme levels
4. Fatigue
5. Weight gain

Rare but serious side effects:

• Risk of cardiovascular events (e.g., heart attack)
• Osteoporosis
• Severe allergic reactions

Precautions

Cardiovascular Health:

• Monitor patients with a history of heart conditions.

Liver Function:

• Periodic liver function tests are recommended.

Bone Health:

• Long-term use may increase the risk of osteoporosis.

Pregnancy:

• Not intended for use in women; harmful if administered during pregnancy.

Allergic Reactions:

• Patients should be monitored for signs of hypersensitivity reactions.

Storage

• Store at 2°C to 8°C (refrigerator).
• Protect from light.